This type of exposure would most likely occur during a bioterrorist attack. This indication was granted under provisions of accelerated approval, on the basis of blood levels achieved in humans and the results of in vitro and animal testing. It has a proven track record of efficacy and safety and has been prescribed more than 250 million times.
Inhalational anthrax is usually fatal.
On July 28, an FDA advisory panel unanimously recommended approval after listening to expert testimony, which included results of an animal study conducted by the Department of Defense. In addition, there are reports indicating that strains of the bacteria have been engineered to resist penicillin and doxycycline. Early administration of ciprofloxacin or other fluoroquinolones has been recommended by The Working Group on Civilian Biodefense 1 . Safety Considerations Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. Monitor theophylline levels if concurrent administration cannot be avoided.